Pakistan approves Chinese Sinopharm COVID -19 vaccine for emergency use

World
Typography

Pakistan reported 1,920 new coronavirus infections and 46 deaths on Monday, taking the total number of cases to more than 521,212 with fatalities approaching 11,000.

 

The Drug Regulatory Authority of Pakistan (Drap) on Monday approved Chinese state-owned firm Sinopharm's COVID-19 vaccine for emergency use, reported Dawn.

Sinopharm is developed by the Beijing Institute of Biological Products, a state-owned subsidiary conglomerate. 

The company had claimed the efficacy rate to be 79.3 per cent from last-stage trials.

Also, it can be stored at two to eight degrees Celsius, or a normal refrigeration temperature.

Earlier, on Friday Drap had authorised the Oxford University-AstraZeneca COVID-19 vaccine for emergency use in Pakistan.

"In a meeting conducted by [the] Registration Board of Drap today January 18, 2021, another vaccine manufactured by China National Pharmaceutical Group (Sinopharm) has also been given EUA (emergency use authorisation)," a spokesperson for the regulatory body said in a statement.

Both the Oxford and Sinopharm vaccines were evaluated for their safety and quality and granted EUA "with certain conditions", the statement added.

"This authorisation will be reviewed on a quarterly basis keeping in view further data regarding safety, efficacy and quality," it said.

China had approved the Sinopharm vaccine for general use in the last month itself. 

It is also been approved in the UAE and Bahrain and is slated for use in Morocco too.

Pakistan reported 1,920 new coronavirus infections and 46 deaths on Monday, taking the total number of cases to more than 521,212 with fatalities approaching 11,000.
 

With inputs from Agency

Image credit: CGTN.com

All Comments